Skip to main content
. 2021 Apr 17;10(2):337–348. doi: 10.1007/s40123-021-00345-2

Table 3.

List of ocular and systemic adverse events in patients receiving intravitreal Ranibizumab biosimilar injections

Adverse event Frequency (%)
Total (number of events/total number of injections [9406]) 1978 (21.03)
nsAE (number of events/total number of injections [9406])
 Subconjunctival hemorrhage 772 (8.2)
 Mild ocular pain 497 (5.27)
 Total 1269 (13.49)
nsADR (number of events/total number of injections [9406])
 Transient blurring of vision 612 (6.5)
 Raised IOP 31 (0.33)
 Mild anterior uveitis 9 (0.1)
 Total 652 (6.93)
SAE (number of events/total number of injections [9406])
 VH 5 (0.05)
 Hyphema 4 (0.04)
 Lens injury 1 (0.01)
 Total 10 (0.1)
sADR (ocular) (number of events/total number of injections [9406])
 RPE tears 31 (0.33)
 Non-infectious vitritis 2 (0.02)
 Infectious endophthalmitis 1 (0.01)
 Total 34 (0.36)
sADR (systemic) (number of events/total number of patients [6404])
 Non-fatal MI 7 (0.12)
 Non-fatal CVA 6 (0.09)
 Total 13 (0.21)

nsAE non-serious adverse event, nsADR non-serious adverse drug reaction, IOP intraocular pressure, SAE serious adverse event, VH vitreous hemorrhage, sADR serious adverse drug reaction, RPE retinal pigment epithelium, MI myocardial infarction, CVA cerebrovascular accident